Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma

BACKGROUND: More than 80% of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) patients harbor the (nucleophosmin) NPM1-ALK fusion gene t(2;5) chromosomal translocation. We evaluated the preclinical and clinical efficacy of ceritinib treatment of this aggressive lymphom...

Descripción completa

Detalles Bibliográficos
Autores principales: Subbiah, V., Kuravi, S., Ganguly, S., Welch, D.R., Vivian, C.J., Mushtaq, M.U., Hegde, A., Iyer, S., Behrang, A., Ali, S.M., Madison, R.W., Venstrom, J.M., Jensen, R.A., McGuirk, J.P., Amin, H.M., Balusu, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8271116/
https://www.ncbi.nlm.nih.gov/pubmed/34242968
http://dx.doi.org/10.1016/j.esmoop.2021.100172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8271116/
https://www.ncbi.nlm.nih.gov/pubmed/34242968
http://dx.doi.org/10.1016/j.esmoop.2021.100172

Ejemplares similares